Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGT007 in Recurrent/Metastatic Refractory Digestive Tract Tumors
NCT06104241Phase 1Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BGT007 in gastrointestinal cancer, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Dose-limiting toxicity at 28 days. Started Oct 2023; status: recruiting.
02
Drugs
BGT007
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT06104241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104241.